Compare MRKR & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | VVOS |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6M | 19.4M |
| IPO Year | N/A | 2020 |
| Metric | MRKR | VVOS |
|---|---|---|
| Price | $1.19 | $2.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $10.25 | $6.75 |
| AVG Volume (30 Days) | ★ 271.0K | 116.0K |
| Earning Date | 11-13-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,694,988.00 | ★ $17,317,000.00 |
| Revenue This Year | N/A | $19.45 |
| Revenue Next Year | $9.06 | $70.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 18.76 |
| 52 Week Low | $0.81 | $1.98 |
| 52 Week High | $5.95 | $7.95 |
| Indicator | MRKR | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 63.24 | 33.84 |
| Support Level | $1.15 | $2.03 |
| Resistance Level | $1.27 | $2.33 |
| Average True Range (ATR) | 0.10 | 0.16 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 87.50 | 4.35 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.